A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit with a PD-1 or PD-L1 inhibitor.
The purpose of this study is to assess whether continuation of pembrolizumab in combination with next-line chemotherapy will prolong progression free survival by RECIST 1.1 criteria in patients who previously benefitted from a PD-1/PD-L1 inhibitor but now have progressive disease as compared to historical controls.
- IRB Number: 1701894485 (BTCRCLUN15-029)
- Research Study Identifier: TX7499
- Principal Investigator: Greg Durm, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required